GlassScriptPhysician profile
Tara Jayant Belsare
NPI 1245355155
$3,353.73
in general payments reported to CMS, 2019-2025
20 companies · $38.28 in 2025
The $38.28 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $247 · 2021: $681 · 2022: $1,242 · 2023: $753 · 2024: $167 · 2025: $38.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.92 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,031.47 | 2020-2023 | Vraylar |
| Alkermes, INC. | $401.34 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $387.84 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $208.97 | 2020-2023 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $201.65 | 2019-2023 | Spravato, Invega Trinza, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $168.26 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $165.50 | 2019-2023 | Trintellix |
| Lundbeck LLC | $161.83 | 2020-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.75 | 2022-2023 | |
| Indivior INC. | $91.69 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $89.08 | 2021-2023 | Ingrezza |
| Axsome Therapeutics, INC. | $70.11 | 2022-2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $58.26 | 2021-2023 | Austedo Xr |
| Allergan, INC. | $46.57 | 2019 | |
| Corium, LLC | $43.03 | 2022-2023 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $38.44 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $30.90 | 2022 | |
| Novo Nordisk INC | $28.55 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.38 | 2022 | |
| Bioxcel Therapeutics, INC. | $15.11 | 2024 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Belsare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.